Oppenheimer Reinstates Outperform on Ionis Pharmaceuticals, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim reinstates Ionis Pharmaceuticals (NASDAQ:IONS) with an Outperform rating and raises the price target from $63 to $65.
February 26, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim reinstates Ionis Pharmaceuticals with an Outperform rating and raises the price target from $63 to $65.
The reinstatement of Ionis Pharmaceuticals by Oppenheimer with an Outperform rating and an increased price target suggests a positive outlook on the company's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100